Immuron's fatty liver disease candidate advancing — 4 insights

Immuron is making progress on three clinical trials for IMM-124E, its nonalcoholic steatohepatitis and nonalcoholic fatty liver disease treatment.

Here's what you should know:

1. Immuron's recruited 133 patients into its first phase II clinical trial, surpassing its goal of 120 patients. Top-line results are expected in the fourth quarter of fiscal year 2017.

2. In Immuron's IMM-124E's alcoholic steatohepatitis clinical study, 50 percent of 66 targeted patients were randomized into the study. Top-line results are expected in the first quarter of fiscal year 2019.

3. Immuron is also in the process of enrolling pediatric patients into a phase II, double blind, placebo-controlled trial of IMM-124E at Atlanta-based Emory University. The study enrolled its first patient in February 2017 and has randomized 20 percent of the 40 patients in the study to date. Results are expected in the fourth quarter of 2017.

4. There are currently no effective treatments for either nonalcoholic steatohepatitis or nonalcoholic fatty liver disease treatment

Immuron CEO Jerry Kanellos PhD said in a release, "We are very pleased with the position of our company and its proprietary technologies within the high growth market for treatments of NASH, NAFLD, and Pediatric NAFLD."

More articles on gastroenterology:
GI leader to know: Dr. Francis Farraye of Boston Medical Center
Stock market week-in-review for 5 large GI companies — Sept. 11-15
Patient engagement, case conference less effective in IBD care than perceived

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers